Navigation Links
Diatos Announces Positive Clinical Results for its DTS-201,Doxorubicin Prodrug Program
Post Your Comments:
(Date:5/16/2008)... Presentations at ASCO Annual Meeting Will Further...ns in Front-line Multiple Myeloma -, CAMBRIDGE, M...icals,The Takeda Oncology Company, today announce...scheduled to be featured at the 2008 American Soci...Chicago, Illinois, May 30 -,June 3, 2008. The data...
(Date:5/16/2008)...peakers include industry and customer thought lead...s, Inc., the recognized,leader and trusted resourc...hosted a constellation of prestigious academic med...artners at its annual user group meeting in San,Fr...rs to internally and,collaboratively manage thousa...
(Date:5/16/2008)...ts Include:, -- Results demonstrating that TYKERB... meaningful extension of progression-free survival...tack both the inside and,outside of the HER2 recep...Data demonstrating activity of TYKERB alone despit... of trastuzumab and chemotherapy, LONDON and PHIL...
(Date:5/16/2008)... N.J., May 16 /- Veridex, LLC announc...ry Corporation of America Holdings,(LabCorp), has ...for,prostate cancer. The new assay uses the biolog...cancer, detecting the methylation of the gene,GST-...rs primarily in,cancer. Veridex is developing the ...
Breaking Medicine Technology:New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 2New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 3New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 4New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 5New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 6New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 7New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 8Top Academic Medical Centers, Research Institutions, and Partners Gather, Share Experiences and Success Stories at Velos eResearch Annual Meeting 2Top Academic Medical Centers, Research Institutions, and Partners Gather, Share Experiences and Success Stories at Velos eResearch Annual Meeting 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 2GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 4GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 5GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 6GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 7Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit 1882 1Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit 1882 2Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit 1882 3Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit 1882 4Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver 1880 1Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver 1880 2Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver 1880 3Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver 1880 4Sleep Apnea Screening Cuts Surgical Complications 17520 1Sleep Apnea Screening Cuts Surgical Complications 17520 2The Quantum Group CEO to Deliver Keynote Address at EDC Life Science Conference 17518 1The Quantum Group CEO to Deliver Keynote Address at EDC Life Science Conference 17518 2The Quantum Group CEO to Deliver Keynote Address at EDC Life Science Conference 17518 3
...h Copaxone Plus Minocycline Showed Substantial,Red...,Relapsing-Remitting Multiple Sclerosis , Combinat...n,Lesions and Was Well Tolerated , KANSAS CITY, Mo...-blind study showed that a combination of Copaxone...l antibiotic,minocycline reduced T1 Gadolinium (Gd...
...o.--(BUSINESS WIRE)--May 4, 2007 - New data from a...ination of,COPAXONE(R) (glatiramer acetate injecti...uced T1 Gadolinium (Gd)-enhancing lesions,of the b...e,relapsing-remitting multiple sclerosis (RRMS), a...mpared to those receiving,COPAXONE(R) alone. Addit...
Other Medicine Technology:Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 2Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 3Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 4Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 5Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 6Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 7Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 8Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 9Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 10Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 11Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 12Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 2Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 3Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 4Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 5
(Date:5/17/2008)... as guide for avoiding exposure , , SAT...e earrings you bought from a hip young street arti...rs and skin. , A new report finds that many pai... Francisco stores and artists contain nickel, whic...d exposure can make treatment difficult. , The ...
(Date:5/16/2008)...ck; Merger Sets Up Healthy Back as the Nation...N, Va., May 16 /PRNewswire/ -- Healthy Back, the 1...ce back wellness created an,ergonomic revolution, ...JoAnne,s Bed & Back. Healthy Back,s 18 stores and ...lion. JoAnne,s 16 mid-Atlantic stores,claimed annu...
(Date:5/16/2008)...yroid hormone readings, study says , , F...tamin D and high levels of a hormone secreted by t...ression in older adults, according to a new report...e of Archives of General Psychiatry , supports pr...depression and other psychiatric illnesses are lin...
(Date:5/16/2008)...e of Oral and Overall Health, HARRISBURG, Pa., Ma...d,Concordia Dental is celebrating National Smile M...and the British Dental Health Foundation to,promot... Beginning May 18,this year,s event is launching ... the largest independent international dental heal...
Breaking Medicine News(10 mins):Health News:Cheaper Earrings More Likely to Contain Nickel 2Health News:Cheaper Earrings More Likely to Contain Nickel 3Health News:The Back Wars Come to a Close 2Health News:Low Vitamin D Tied to Depression in Older Adults 2Health News:United Concordia Dental Celebrates National Smile Month 2
...handigarh is all set to turn into a "no-smoking zo...horities, the ban would be fully enforced from Jul.... Smoking kills over a million of the 250 million ...country. The establishment says it will not make...
... new study has found that weight management progra...easing weight, body fat, body mass index (BMI) in ...ement program developed by researchers at Yale Sch...at plummeting weight, body fat, BMI and insulin se...
...ndian neuroscientists are part of an international...s of mental retardation and autism in mice, raisi...fects one in 500 children. Researchers at the Nat... (NCBS) and National Institute of Mental Health an...
...learly a new wind is blowing across in three key a... are sick, literally and metaphorically, one might...respective governments seem to have failed the peo...king off a major healthcare crisis. The powers-tha...
Other Medicine News:Health News:Chandigarh Set to Be No-smoking Zone from July 15 2Health News:Bright Bodies Weight Program Lowers Diabetes Risk, BMI in Obese Kids 2Health News:Research Shows Way for Drug Therapy for Autism 2Health News:Back to Basics in Health in Advanced Countries Now 2Health News:Back to Basics in Health in Advanced Countries Now 3Health News:Back to Basics in Health in Advanced Countries Now 4
Inquire
Measles IgM Enzyme-Linked Immunosorbent Assay (ELISA) is intended for the in vitro determination of Measles IgM antibodies in human serum. For in vitro diagnostic use. High complexity test.
...nzymelinked Immunosorbent Assays(ELISA) is intende... of IgG antibody to Measles Rubeola) virus in huma... the determination of immune status. Paired sera, ...te seroconversion or a significant rise in antibod...
The Diagnostic Automation, Inc. (DAI) Measles IgM Enzyme-Linked Immunosorbent Assay (ELISA) is intended for the in vitro determination of IgM antibody to Measles in human serum.
Medicine Products: